Stocktoria
OCULAR THERAPEUTIX, INC OCUL
OCULAR THERAPEUTIX, INC financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $52.0M | $63.7M | $58.4M | $51.5M | $43.5M | $17.4M | $4.2M | $2.0M | $1.9M | $1.9M |
| R&D expense | $197.1M | $127.6M | $61.1M | $53.5M | $50.1M | $28.7M | $41.1M | $36.9M | $30.9M | $27.1M |
| Operating income | -$270.0M | -$171.8M | -$82.4M | -$78.7M | -$78.0M | -$62.8M | -$85.8M | -$59.1M | -$61.9M | -$43.3M |
| Interest expense | — | — | $11.3M | $7.0M | $6.7M | $6.8M | $6.1M | $1.7M | $1.9M | $1.7M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$265.9M | -$193.5M | -$80.7M | -$71.0M | -$6.6M | -$155.6M | -$86.4M | -$60.0M | -$63.4M | -$44.7M |
| EPS (diluted) | $-1.42 | $-1.22 | $-1.02 | $-0.97 | $-0.98 | $-2.56 | $-1.91 | — | — | — |
| Operating cash flow | -$204.9M | -$134.7M | -$70.2M | -$59.6M | -$65.5M | -$53.6M | -$77.6M | -$49.2M | -$50.5M | -$34.0M |
| Free cash flow | -$216.9M | -$136.0M | -$76.3M | -$63.3M | -$66.7M | -$54.4M | -$79.8M | -$51.1M | -$58.7M | -$35.9M |
| Cash & equivalents | $737.1M | $392.1M | $195.8M | $102.3M | $164.2M | $228.1M | $54.4M | $54.1M | $41.5M | $32.9M |
| Inventory | $3.6M | $3.0M | $2.3M | $2.0M | $1.2M | $1.2M | $954,000 | $217,000 | $122,000 | $113,000 |
| Total assets | $808.1M | $457.9M | $252.1M | $149.3M | $204.9M | $261.9M | $78.7M | $73.0M | $55.4M | $74.9M |
| Total liabilities | $153.7M | $142.6M | $160.9M | $113.9M | $116.9M | $185.8M | $82.4M | $37.2M | $29.3M | $22.9M |
| Shareholders' equity | $654.3M | $315.3M | $91.1M | $35.4M | $88.0M | $76.1M | -$3.6M | $35.9M | $26.1M | $52.0M |
Growth · year-over-year · Revenue CAGR 44.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -18.5% | +9.0% | +13.5% | +18.3% | +150.1% | +311.7% | +112.4% | +3.5% | +1.9% | +7.8% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.